What does this research mean for the field?

Selective inhibition of thromboxane synthase fails to suppress platelet activation in patients with severe peripheral vascular disease, likely due to the accumulation of proaggregatory endoperoxides. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

June 1, 1986CirculationOpen Access

Increased thromboxane biosynthesis in a human preparation of platelet activation: biochemical and functional consequences of selective inhibition of thromboxane synthase.

View Full Paper

Ask AI

Bookmark

Why the study?

Does imidazo (1,5-2) pyridine-5-hexanoic acid alter platelet aggregation and bleeding time in patients with severe peripheral vascular disease?

Structured PICO

Does imidazo (1,5-2) pyridine-5-hexanoic acid alter platelet aggregation and bleeding time in patients with severe peripheral vascular disease?

Population

Patients with severe peripheral vascular disease selected on the basis of elevated plasma beta-thromboglobulin and circulating platelet aggregates, and healthy, age-matched control subjects.

Intervention

Imidazo (1,5-2) pyridine-5-hexanoic acid (a selective inhibitor of thromboxane synthase)

Comparator

Control conditions (double-blind, controlled)

Outcome

Platelet aggregation ex vivo, circulating platelet aggregate ratio, and bleeding timesurrogate

Selective inhibition of thromboxane synthase does not prevent platelet activation in severe peripheral vascular disease, suggesting that combined receptor antagonism may be necessary.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Selective thromboxane synthase inhibition alone may not suffice in severe PVD; challenges monotherapy and supports combined receptor antagonism trials.

Cite This Study

Reilly et al. (1986) studied this question.

synapsesocial.com/papers/6a1c039626cb5670aa9d413e https://doi.org/10.1161/01.cir.73.6.1300

View Full Paper

Ask AI

Bookmark

Implication

Selective thromboxane synthase inhibition alone may not suffice in severe PVD; challenges monotherapy and supports combined receptor antagonism trials.